FORM 4

(Print or Type Responses)

-	Check this box if no
	longer subject to Section
	16. Form 4 or Form 5
	obligations may continue.
	See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

1474 (9-02)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Ro Welch David F		2. Issuer Name and Ticker or Trading Symbol CytoDyn Inc. [CYDY]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner			
(Last) 1111 MAIN STREET	(First) F, SUITE 660		3. Date of Earliest Transaction (Month/Day/Year) 09/30/2019					Officer (give title below) Other (specify below)		
VANCOUVER, WA	4.	4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year	2A. Deemed Execution Date, if any (Month/Day/Year)	(Instr. 8)		or Disposed of (D)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Direct (D)	Beneficial Ownership
				Code	v	Amount	(A) or (D)	Price		or Indirect (I) (Instr. 4)	(Instr. 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this	SEC
form are not required to respond unless the form displays a currently	
valid OMB control number.	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	Price of	Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	tion	5. Number of Securities Ac or Disposed o (Instr. 3, 4, at	equired (A) of (D)	 Date Exerci Expiration Dat (Month/Day/Y) 	te	Underlying Securities (Instr. 3 and 4)		Derivative Security	Securities	Ownership	Beneficial
	Derivative Security			Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Owned Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect	(Instr. 4)
Convertible Promissory Note	\$ 0.5	09/30/2019		D			1,000,000	01/30/2019	10/01/2019	Common Stock	2,000,000	<u>(2)</u>	\$ 0	Ι	See Footnote (1)
Convertible Promissory Note	\$ 0.5	09/30/2019		А		1,075,343		09/30/2019	04/01/2020	Common Stock	2,150,686	<u>(2)</u>	\$ 1,075,343	Ι	See Footnote (1)
Warrant (Right to Buy)	\$ 0.3	09/30/2019		A		1,000,000		09/30/2019	09/30/2024	Common Stock	1,000,000	<u>(2)</u>	1,000,000	Ι	See Footnote (1)

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Welch David F 1111 MAIN STREET, SUITE 660 VANCOUVER, WA 98660	Х						

Signatures

/s/ Michael D. Mulholland, as attorney-in-fact	01/08/2020
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reported securities of CytoDyn Inc. (the "Company") are held by LRFA, LLC, a Delaware limited liability company ("LRFA"). David F. Welch, Ph.D. is the sole managing member of LRFA. Dr. Welch disclaims beneficial ownership of the securities held by LRFA, except to the extent of his pecuniary interest therein.
- The Company recently completed a convertible promissory note exchange offer in which LRFA participated, among other non-affiliated investors. Pursuant to the exchange offer, as an inducement to extend the maturity date of a certain convertible promissory note (the "Original Note") beneficially owned by Dr. Welch, the Company (i) issued a new convertible promissory note (the "Exchange Note") in the principal amount of the Original Note plus the accrued but unpaid interest thereon and (ii) issued a warrant to purchase shares of common stock covering fifty percent of the shares of common stock into which the principal amount of the Original Note was convertible.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.